PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20813706-0	2010	[Therapeutic efficacy of Nexavar on liver cancer and its relation to the expression of Ki-67 and CD34].	Sorafenib	25-32	CD34 molecule	Homo sapiens	97-101	
20813706-1	2010	OBJECTIVE: To study the therapeutic effects of Nexavar on liver cancer and its relation to the expressions of Ki-67 and CD34.	Sorafenib	47-54	CD34 molecule	Homo sapiens	120-124	
17595328-2	2007	When administered at pharmacologically relevant concentrations (10-15 microM), sorafenib potently induced apoptosis in imatinib mesylate-resistant cells expressing high levels of Bcr/Abl, cells exhibiting a Bcr/Abl-independent, Lyn-dependent form of resistance, and CD34(+) cells obtained from imatinib-resistant patients.	Sorafenib	79-88	CD34 molecule	Homo sapiens	266-270	
17178882-10	2006	In mechanism of action studies, sorafenib inhibited the phosphorylation of both ERK and eIF4E, reduced the microvessel area (assessed by CD34 immunohistochemistry), and induced tumor cell apoptosis (assessed by terminal deoxynucleotidyl transferase-mediated nick end labeling) in PLC/PRF/5 tumor xenografts.	Sorafenib	32-41	CD34 molecule	Homo sapiens	137-141	
16498671-8	2006	Furthermore, normal donor CD34+ve stem cells were much more sensitive to BAY 43-9006 when ERK was activated by SCF, compared to PMA.	Sorafenib	73-84	CD34 molecule	Homo sapiens	26-30	
34876355-11	2021	Levels of a CD34+KDR+ are higher at baseline in patients responding to sorafenib.	Sorafenib	71-80	CD34 molecule	Homo sapiens	12-16